About MeiraGTx Holdings plc - Ordinary Shares (MGTX)
Meiragtx Holdings Plc is a biotechnology company focused on developing innovative genetic therapies to address significant unmet medical needs. The company leverages its advanced gene editing technology to create treatments for various rare and serious diseases, particularly those affecting the eye and central nervous system. By harnessing the power of gene therapy, Meiragtx aims to provide long-lasting solutions that target the underlying causes of genetic disorders, with a commitment to improving patient outcomes and quality of life. Through its research and clinical programs, the company is dedicated to pioneering advancements in the field of genetic medicine. Read More
BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system (“CNS”) indications, into focus as strategic assets aligned with current M&A priorities. The company just announced key advancements in its global intellectual property portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform. The advancements strengthen protection across neurology, oncology and central nervous system (“CNS”) drug delivery designed to delivery drugs into the brain by getting through the blood brain barrier. This M&A trend bolsters Oncotelic Therapeutics’ position in the oncology and CNS sectors as the OTLC joins other companies focused on the space, including Arrowhead Pharmaceuticals Inc . (NASDAQ: ARWR), MeiraGTx Holdings plc (NASDAQ: MGTX), Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) and…
AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system (CNS) indications, into focus as strategic assets aligned with current M&A priorities. The company just announced key advancements in its global intellectual property portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform. The advancements strengthen protection across neurology, oncology and central nervous system (CNS) drug delivery designed to deliver drugs into the brain by getting through the blood brain barrier. This M&A trend bolsters Oncotelic Therapeutics’ position in the oncology and CNS sectors as OTLC joins other companies focused on the space, including Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), MeiraGTx Holdings plc (NASDAQ: MGTX), Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) and Johnson & Johnson (NYSE: JNJ).
As of December 18, 2025, the financial landscape is defined by a stark divergence in the commodities market, creating a complex environment for clinical-stage biotechnology firms. While gold prices have surged to record highs near $2,700 per ounce, signaling a defensive "risk-off" posture among global investors, energy prices have
LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in the area of ophthalmology with Eli Lilly and Company (“Lilly”).
- Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX) to support a potential Biologics License Application (BLA) filing; on track for potential data readout late 2026
- Announced strategic collaboration with Hologen AI, including a $200 million cash upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus on expediting Phase 3 clinical development of AAV-GAD for Parkinson’s disease
- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson’s disease
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.
- Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus on expediting Phase 3 clinical development of AAV-GAD for Parkinson’s disease
LONDON and NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the publication of results from the first-in-human interventional study to treat children with AIPL1-associated severe retinal dystrophy. The data were published in The Lancet in a paper titled, "Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study". This paper presents data from the first 4 children treated unilaterally with rAAV8.hRKp.AIPL1. A further 7 children with LCA4 were treated bilaterally with rAAV8.hRKp.AIPL1 demonstrating similarly remarkable effects on vision, with all 11 of the 11 children treated who were blind at birth now having visual acuity in the treated eyes.
MeiraGTx has recently received Rare Pediatric Disease Designation (RPDD) for four inherited retinal diseases (IRDs) reflecting the transformative therapeutic potential of the Company’s proprietary technology platforms
